dc.creatorPetricoin, EF
dc.creatorOrnstein, DK
dc.creatorPaweletz, CP
dc.creatorArdekani, A
dc.creatorHackett, PS
dc.creatorHitt, BA
dc.creatorVelassco, A
dc.creatorTrucco, C
dc.creatorWiegand, L
dc.creatorWood, K
dc.creatorSimone, CB
dc.creatorLevine, PJ
dc.creatorLinehan, WM
dc.creatorEmmert Buck, MR
dc.creatorSteinberg, SM
dc.creatorKohn, EC
dc.creatorLiotta, LA
dc.date.accessioned2024-01-10T12:08:31Z
dc.date.accessioned2024-05-02T16:26:33Z
dc.date.available2024-01-10T12:08:31Z
dc.date.available2024-05-02T16:26:33Z
dc.date.created2024-01-10T12:08:31Z
dc.date.issued2002
dc.identifier0027-8874
dc.identifierMEDLINE:12381711
dc.identifierhttps://repositorio.uc.cl/handle/11534/76400
dc.identifierWOS:000178562900013
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9266263
dc.description.abstractPathologic states within the prostate may be reflected by changes in serum proteomic patterns. To test this hypothesis, we analyzed serum proteomic mass spectra with a bioinformatics tool to reveal the most fit pattern that discriminated the training set of sera of men with a histopathologic diagnosis of prostate cancer (serum prostate-specific antigen [PSA] greater than or equal to 4 ng/mL) from those men without prostate cancer (serum PSA level < 1 ng/mL). Mass spectra of blinded sera (N = 266) from a test set derived from men with prostate cancer or men without prostate cancer were matched against the discriminating pattern revealed by the training set. A predicted diagnosis of benign disease or cancer was rendered based on similarity to the discriminating pattern discovered from the training set. The proteomic pattern correctly predicted 36 (95%, 95% confidence interval [CI] = 82% to 99%) of 38 patients with prostate cancer, while 177 (78%, 95% CI = 72% to 83%) of 228 patients were correctly classified as having benign conditions. For men with marginally elevated PSA levels (4-10 ng/mL; n = 137), the specificity was 71%. If validated in future series, serum proteomic pattern diagnostics may be of value in deciding whether to perform a biopsy on a man with an elevated PSA level.
dc.languageen
dc.publisherOXFORD UNIV PRESS INC
dc.rightsregistro bibliográfico
dc.subjectPROTEIN BIOCHIP
dc.subjectANTIGEN
dc.titleSerum proteomic patterns for detection of prostate cancer
dc.typeartículo


Este ítem pertenece a la siguiente institución